Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Entrada Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$6.46

+0.15 (+2.38%)

D 29Pipeline Score Richly Valued Biotech · Commercial
Market Cap
254.66 M
EPS
-4.00
P/E Ratio
-
Value Trade
1.57 M
SEC Financials
Q1 2026

  • Dilution Risk

    25%

  • Revenue

    875.00 K

  • R&D Expenses

    33.05 M

  • Operating CF

    -41.70 M

  • Total Assets

    335.52 M

  • Total Liabilities

    64.66 M

  • Equity

    270.85 M

  • D/E Ratio

    12,345

-1.5 %
Week
-50.23 %
1 Month
-42.2 %
3 Month
-28.38 %
6 Month
-75.25 %
5 Year
-75.25 %
All Time
Cash Data
Stable

  • Cash Position

    254.86 M

  • Monthly Burn

    13.90 M

  • Runway

    17.2 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 7, 2026
Overview
Volume
185.97 K
52 Week Range
4.93 - 16.45
% held by Insiders
43.4 %
% held by Institutions
48.22 %
Enterprise Value
49.55 M
Total Shares
38.20 M
Short %
7.21 %
Float Shares
23.95 M
Company Description
HQ: ONE DESIGN CENTER PLACE, BOSTO...
Employees:152
https://www.entradatx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 1/2 data readout example
ENTR-601-45 Duchenne muscular dystrophy (exon 45 skipping amenable)
Phase 1/2
—
RNA-Based Therapies
Musculoskeletal System
ENTR-601-45 Duchenne muscular dystrophy (exon 45 skipping amenable)
Phase 1/2
—
RNA-Based Therapies
Musculoskeletal System
ENTR-601-45 Duchenne muscular dystrophy (exon 45 skipping amenable)
Phase 1/2
—
RNA-Based Therapies
Musculoskeletal System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D29
Pipeline Score
$9M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 30%
Micro Cap
(rank 634 of 905)
Percentile Rank
Entrada Therapeutics, Inc. faces pipeline headwinds (29/100), with $80M risk-adjusted pipeline value, led by ENTR-601-44 in Duchenne Muscular Dystrophy (DMD) (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
ENTR-601-44
Small molecule		Duchenne Muscular Dystrophy (DMD)Phase 1NCT0703786211% $40M RECRUITING 24 AVERAGE B (73) Mar 28, 2029MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
ENTR-601-44, ENTR-601-45
Duchenne muscular dystrophy
Phase 1/2
2025-08-06
ENTR-601-44, ENTR-601-45
Duchenne muscular dystrophy
Phase 1/2
2025-08-06
ENTR-601-44, ENTR-601-45
Duchenne muscular dystrophy
Phase 1/2
2025-08-06
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in TRDA
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
TRDA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TRDA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TRDA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
TRDA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
TRDA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Entrada Therapeutics, Inc. (TRDA) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How TRDA ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Rare Neurological Disorders #34 of 46 PHASE 1 ENTR-601-44
IONS BIIB SRPT
$139.4B 0.81 FOLLOWER